SaharSamimiMD

IM Resident @BCM_InternalMed; CV research alumni @MayoClinicCV @HMethodistCV

[SaharSamimiMD @SaharSamimiMD]

@haisummaqsood @HMHCardioFellow @HMethodistCV @WilliamZoghbi @SLittleMD @khurramn1 @AlpeshShahMD @n_kleiman Congrats Haisum!!

[SaharSamimiMD @SaharSamimiMD]

@BrdKhsrv @SIIM_Tweets @RSNA @YaleRadiology That’s amazing. Congrats, Bardia!!

[Mayra Guerrero, MD @MayraGuerreroMD]

The primary endpoint and 1-year outcomes of the ENCIRCLE MAC Registry were presented as an LBCT at New York Valves (June 25, 2026). This is the first pivotal evaluation of fully percutaneous transseptal TMVR in patients with MAC-related mitral valve dysfunction using a dedicated mitral THV. Patients with symptomatic MAC-related mitral valve dysfunction treated with transseptal TMVR using the SAPIEN M3 system had 30-day mortality lower than predicted by the STS score, durable MR reduction to ≤1+, sustained improvements in symptoms and quality of life, and stable THV performance through 1 year. These findings support consideration for transseptal TMVR with SAPIEN M3 as a treatment option for appropriately selected patients with symptomatic MAC-related mitral valve dysfunction.
@MayoClinicCV #NYValves #TMVR #StructuralHeart #MitralValve #MAC #SAPIENM3

[CardioTechx @CardioTechx]

🧠🫀 LLMs for heart failure research dataset curation
In DELIVER + PARAGON-HF, an LLM extracted 16 admission features from 1,534 first HF hospitalization dossiers with ~0.96 accuracy.
@JCardFail @akshaydesaimd @patrick_ellinor @scottdsolomon
Paper: https://t.co/JBd6J15wGE

[Sachin Goel @SachinGoelMD]

Honored to present our late‑breaking CoreValve/Evolut TAVR durability data @crfheart #NYValves2026: <3% reintervention, <6% bioprosthetic valve failure at 8 yrs, SVD main failure mechanism. Proud of our fellows’ contributions and grateful for the chance to share and learn.

[Mangesh Kritya @KrityaMangesh]

Many congratulations to my PI and mentor Dr. @SachinGoelMD on his presentation at Late-Breaking Clinical Science session at #NYValves!

It was a privilege to work with the incredible team at @HMethodistCV.

#TAVR #StructuralHeart

[Saliha Erdem MD @mderdem3]

Just grabbed a quick 🎥 with Dr @SachinGoelMD after his 8‑year Evolut durability presentation at #NYValves2026 🫀 @crfheart

[Chloe Kharsa @KharsaChloe]

Our single-center experience on 8-year durability & reintervention after TAVR with the Evolut valve, presented at #NYValves2026 @crfheart by @SachinGoelMD
Proud to be part of the @HMethodistCV dream team🫀

[SaharSamimiMD @SaharSamimiMD]

Grateful for our Houston Methodist family 🫶

[Saliha Erdem MD @mderdem3]

🫀🏥🤝

The Houston Methodist family; past and present; at #NYValves2026. Proud to see such a strong presence 🙌🏻

@crfheart @TCTMD @TCTConference

[CardioTechx @CardioTechx]

🚨🫀 AI-ECG for heart failure screening in Kenya

AI-ECG detected LV systolic dysfunction with:
✅ AUC 0.96
✅ Sensitivity 95.6%
Great work @ambarish4786 @NeilKeshvani @MattSegar @JAMACardio
Paper: https://t.co/WJvB2ZDEJj
#CardioTwitter #AIinMedicine #GlobalHealth #HeartFailure

[SaharSamimiMD @SaharSamimiMD]

You don’t want to miss this #TAVR late-breaking session tomorrow at #NYValves2026:

7-year PARTNER 3 durability
7-year low-risk BEV outcomes
VA-CART Evolut data
8-year Evolut durability
6-year Evolut low-risk bicuspid outcomes
Updated EARLY-TAVR results

⏰ June 24 | 10:15 AM
📍 Heart Team Arena, Level 4, Room 406
@crfheart

[David J. Cohen, MD, MSc @djc795]

@willsuh76 @drjohnm Looking forward to Philippe Pibarot's in-depth presentation of echocardiographic f/u of the PARTNER 3 trial (S3 vs. SAVR) at #NYValves2026 next week. This should provide the best comparative data performance of "relatively" contemporary BE valves vs. SAVR. @crfheart

[Carlos E. S. @CAESmedmd]

Heading back home to NYC for #NYValves2026! 🗽🫀
As an ambassador & incoming cardiology fellow, I’m hyping up the biggest structural heart drops of the year:
🔥 PARTNER 3 (7-yr durability)
🔥 EARLY TAVR (Asymptomatic AS intervention)
Follow me & @crfheart for the live drops! 📲

[SaharSamimiMD @SaharSamimiMD]

Round two! Old account got hacked, but #NYValves2026 feels like a great reason to return to X.

Lots of exciting LBCT ahead: Long-term #TAVR durability, new data on EARLY TAVR and #TMVR in MAC, #Tricuspid phenotyping and re-do #MTEER.

Excited to be back for it! 🗽

June 24–26 | Javits Center, NYC @crfheart